Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 4/20 | 1.00 |
| ▸ | SORT1 | Q99523 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600233 | 0.89 | GRN (0.80) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL4718807 | 0.88 | GRN (0.78) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL12705325 | 0.88 | GRN (0.78) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL2787544 | 0.87 | GRN (0.76) | GRNSORT1KDM4EMAPK13MAPK12 | |
| SCHEMBL16749343 | 0.87 | GRN (0.76) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL2314764 | 0.86 | GRN (0.74) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL16739360 | 0.84 | GRN (0.72) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL950904 | 0.84 | GRN (0.72) | GRNSORT1ALDH1A1GAAKDM4E | |
| SCHEMBL18277669 | 0.84 | GRN (0.72) | GRNSORT1ALDH1A1KDM4EMAPK13 | |
| SCHEMBL15485403 | 0.84 | GRN (0.72) | GRNSORT1ALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | claimed |
| EP-4225280-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | Insusense ApS (DK) | 2023-08-16 | — | — | EP | claimed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2022074119-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | INSUSENSE ApS (DK) | 2022-04-14 | — | — | WO | claimed |
| EP-3981394-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS. | Insusense ApS (DK) | 2022-04-13 | — | — | EP | claimed |
| EP-2112150-B1 | Improved raf inhibitors | FORMA THERAPEUTICS INC (US) | 2013-10-16 | — | — | EP | claimed |
| US-8232283-B2 | Raf inhibitors | FORMA THERAPEUTICS, INC. (US) | 2012-07-31 | — | — | US | claimed |
| EP-2112150-A1 | Improved raf inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | claimed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | VESPER BIO APS (DK) | 2023-11-23 | — | — | US | disclosed |
| EP-4225280-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | Insusense ApS (DK) | 2023-08-16 | — | — | EP | disclosed |
| CN-116194096-A | Sortilin antagonists for preventing and treating hearing impairment | 因苏森斯有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| US-7977477-B2 | Benzimidazole derivatives and their use as protein kinase inhibitors | ASTEX THERAPEUTICS, LIMITED (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009130015-A1 | IMPROVED RAF INHIBITORS | GPC BIOTECH AG (DE) | 2009-10-29 | — | — | WO | disclosed |
| EP-2112150-A1 | Improved raf inhibitors | GPC Biotech AG (DE) | 2009-10-28 | — | — | EP | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224203-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CCNI, CDK2 | GRN 3428/4885SORT1 4786/4885ALDH1A1 2449/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | GRN 3957/4885SORT1 4660/4885ALDH1A1 1157/4885 |
| US-20230374143-A1 | A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS | SORT1, NTSR2, SLC17A5 | GRN 448/4885SORT1 1/4885ALDH1A1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.